VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity

ElTanbouly, Mohamed; Croteau, Walburga; Noelle, Randolph J.; Lines, J. Louise

doi:10.1016/j.smim.2019.101308

Cited by 105 publications

(105 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The immune checkpoint therapy of tumors has revealed a potential relationship between VISTA and PD-L1. These two molecules show not only similar homology but also consistent expression after treatment with ipilimumab (93). This relationship provides a new perspective for investigating and treating PD-L1-related pregnancy complications.…”

Section: B7-h5mentioning

confidence: 61%

The Role of B7 Family Molecules in Maternal–Fetal Immunity

2020

View full text Add to dashboard Cite

Pregnancy is a complex but well-arranged process, and a healthy fetus requires immune privilege and surveillance in the presence of paternally derived antigens. Maternal and fetal cells interact at the maternal-fetal interface. The upregulation and downregulation of maternal immunity executed by the leukocyte population predominantly depend on the activity of decidual natural killer cells and trophoblasts and are further modulated by a series of duplex signals. The B7 family, which consists of B7-1, B7-2, B7-H1, B7-DC, B7-H2, B7-H3, B7-H4, B7-H5, BTNL2, B7-H6, and B7-H7, is one of the most characterized and widely distributed signaling molecule superfamilies and conducts both stimulatory and inhibitory signals through separate interactions. In particular, the roles of B7-1, B7-2, B7-H1, and their corresponding receptors in the progression of normal pregnancy and some pregnancy complications have been extensively studied. Together with the TCR-MHC complex, B7 and its receptors play a critical role in cell proliferation and cytokine secretion. Depending on this ligand-receptor crosstalk, the balance between the tolerance and rejection of the fetus is perfectly maintained. This review aims to provide an overview of the current knowledge of the B7 family and its functions in regulating maternal-fetal immunity through individual interactions.

show abstract

Section: B7-h5mentioning

confidence: 61%

The Role of B7 Family Molecules in Maternal–Fetal Immunity

2020

View full text Add to dashboard Cite

show abstract

“…CD44, a molecule that -among other things -is expressed on activated T cells (12,13), was present at higher levels in FOL-FIRINOX-treated patients than in surgery-alone patients ( Figure 3B). VISTA, an immunosuppressive checkpoint molecule (14), was expressed at significantly lower levels in F + SBRT-treated patients than in surgery-alone patients ( Figure 3B). Neoadjuvant therapy was also associated with significant differences in the amount of CD45 and several proteins that serve as markers of immune cell type (CD4, CD45, CD56, CD68; Figure 3C).…”

Section: Resultsmentioning

confidence: 99%

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy

Farren¹,

Sayegh²,

Ware³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…In VISTA‐deficient mice, B16‐OVA melanoma and CT26 colon cancer tumors grow with reduced kinetics , and VISTA‐deficient mice also show reduced susceptibility to GL261 glioma, particularly when undergoing radiation therapy . Cells mediating VISTA suppression may be of both the T cell and myeloid lineages . Myeloid‐derived suppressor cells (MDSC) from an LP‐BM5 virus model showed a significant dependence on VISTA for suppressive function .…”

Section: The Promise Of Vista In Cancer Immunotherapymentioning

confidence: 99%

“…While the role of PSGL‐1 is not clearly established in microglia, VISTA plays a critical regulatory role as a checkpoint of microglia activation and restricts their proinflammatory polarization . Both VISTA and PSGL‐1 are also highly expressed on granulocytes, macrophages and endothelial cells and play important functions in their biology . From the perspective of immune cell function, there are interesting parallels between VISTA and PSGL‐1 on the outcome of immune responses.…”

Section: The Vista Ligand Mysterymentioning

confidence: 99%

VISTA: Coming of age as a multi-lineage immune checkpoint

ElTanbouly

Schaafsma

Noelle

et al. 2020

Clinical and Experimental Immunology

Self Cite

View full text Add to dashboard Cite

The immune response is governed by a highly complex set of interactions among cells and mediators. T cells may be rendered dysfunctional by the presence of high levels of antigen in the absence of co-stimulation while myeloid cells may be programmed towards an immunosuppressive state that promotes cancer growth and metastasis while deterring tumor immunity. In addition, inhibitory programs driven by immune checkpoint regulators dampen anti-tumor immunity. The ideal cancer immunotherapy treatment will improve both cross-priming in the tumor microenvironment and relieve suppression by the inhibitory checkpoints. Recently, blockade of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has elicited impressive results, but not in all patients, so additional targets are under investigation. V-set immunoglobulin domain suppressor of T cell activation (VISTA) is a novel immunoregulatory receptor that is broadly expressed on cells of the myeloid and lymphoid lineages, and is frequently implicated as a poor prognostic indicator in multiple cancers. Importantly, antibody targeting of VISTA uniquely engages both innate and adaptive immunity. This, combined with the expression of VISTA and its non-redundant activities compared to other immune checkpoint regulators, qualifies VISTA to be a promising target for improving cancer immunotherapy.

show abstract

VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity

Cited by 105 publications

References 64 publications

The Role of B7 Family Molecules in Maternal–Fetal Immunity

The Role of B7 Family Molecules in Maternal–Fetal Immunity

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy

VISTA: Coming of age as a multi-lineage immune checkpoint

Contact Info

Product

Resources

About